enhancing maize yield by manipulating the control of stem cell proliferation, meristem size and ear growth. Moreover, with 45 CLE peptides in maize 4 , opportunities abound for tinkering with regulating feedback signals that may, like in the case of ZmFCP1, emanate from the developing primordia. The findings contribute potential loci to the myriad genetic targets that may improve crop productivity in the modern era, either through mining of alleles in diversity panels or through targeted genome editing.
progenitor 15 . Indeed, a previous study by Jackson and colleagues showed that weak alleles of fea2 (the maize clv2 ortholog) significantly increased maize kernel row number, and suggested fea2 was likely targeted during crop improvement 3 . Turning to their newly discovered FEA3-ZmFCP1 pathway, Je and colleagues demonstrated another strategy to improve agronomic traits in the ear (kernel row number, total kernels per ear, and ear weight) by tweaking the CLV-WUS-FEA3 circuit. Upon generating F 1 maize hybrid populations with two independent, weak alleles of fea3, Je et al. found a sizable increase in ear traits. This work offers significant promise for further that were resistant to the CLE27 ligand. These comparative analyses demonstrate that FEA3 function is deeply conserved in plant evolution, as monocots and eudicots diverged over 150 million years ago 14 .
Meristem size influences yield
Meristem size, which translates to grain production and fruit size, has been subjected to intense selection during domestication and crop improvement 2, 3, 15 . The monstrous ear of modern maize comprises a lateral branch that is produced by an axillary meristem and yields approximately 50 times more kernels relative to the smaller ear of its wild teosinte Figure 1 Primordial signaling regulates meristem size. Left, the maize CLE peptide ZmFCP1, expressed in developing primordia (P0-P2), signals to the SAM where it interacts with the FEA3 receptor. FEA3 suppresses ZmWUS expression to regulate stem cell proliferation through feedback. Right, whether expression of Arabidopsis CLE27 and AtFEA3 localizes similarly to control meristem size remains to be seen.
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Perhaps a wee bit of sugar would help
Hudson H Freeze
a new genetic disorder might be treatable through consumption of a simple sugar, but the relative contributions of endogenous and dietary sources are mostly unknown. it's time to change that.
Fewer than 10% of the 5,500 disorders with a known molecular basis can claim a therapy, but suppose treatment could be as simple as consuming the right sugar. That is the suggestion of a report published in the current issue of Nature Genetics (ref. 1). Sugars required for protein glycosylation can be made de novo, salvaged from degraded glycans or captured from the diet. The problem is that we don't know how much each pathway contributes to glycosylation in different cells or at different times in development, so we cannot predict whether a sugar supplement could be beneficial.
Brains and bones need glycosylation
Karnebeek, Bonafé, Wen et al. 1 combined state-of-the-art genetic and metabolic analysis to define a new congenital disorder of glycosylation (CDG) that selectively impairs skeletal and brain development. Mutations in NANS partially block the de novo pathway for N-acetylneuraminic acid (NeuNAc; also known as sialic acid, Sia), a critical sugar found in glycoproteins and glycolipids of all human cells (Fig. 1) .
The team identified eight individuals with intellectual development disorder (IDD) who had similar facial dysmorphisms, skeletal dysplasia, short stature and other bone abnormalities. Next-generation sequencing identified various substitutions, insertions, duplications and splice-altering intronic mutations in NANS. In silico protein modeling positioned mutations in or near the active site or at a critical dimer-forming interface, while others predicted protein misfolding. Molecular predictions require functional confirmation. NANS activity for the reaction N-acetylmannoseamine-6-P (ManNAc-6-P) + phosphoenolpyruvate (PEP) → N-acetylneuraminate-9-P is required for the de novo biosynthesis of sialic acid (Fig. 1) , and the fibroblasts of these patients showed a ~75% deficiency in enzymatic activity.
npg volume 48 | number 7 | July 2016 | nature genetics caused by mutations in GNE (affecting UDPGlcNAc → ManNAc-6-P) 5 (clinicaltrials.gov IDs NCT02346461, NCT02639260 and NCT02377921). GlcNAc has been successful for treating children with severe treatmentresistant inflammatory bowel disease 6 and is being tested on patients with PGM3-CDG (affecting GlcNAc-6-P → GlcNAc-1-P, the latter a precursor of activated UDP-GlcNAc) 7 (clinicaltrials.gov ID NCT02511041). Other studies in mouse models of multiple sclerosis show that adding modest amounts of GlcNAc to the drinking water improves their clinical outcome 8 . Human therapeutic trials are pending.
Except for extensive studies of mannose 9,10 , very little is known about the relative or absolute contributions of de novo, salvage and dietary sources of these monosaccharides to cellular glycosylation. Incorporation of appropriately tagged stable (heavy) isotope-labeled precursors provides good estimates of different sources 10 . Meaningful experiments in cells require physiological concentrations of the relevant monosacccharides, such as glucose, which is often included in standard media at 10-25 mM rather than at a physiological concentration of ~5 mM. Sialic acid salvaged from degraded glycans by some tissues or cells would probably account for selective impact of the NANS mutations on glycosylation in selected organs. The current study did not define cellular conditions that deplete sialylated glycans and titrate sialic acid to restore the normal state. Clearly, 200 µM sialic acid is sufficient to rescue zebrafish over a defined time frame, but this cannot be generalized to patients with NANS-CDG. The authors correctly advocate extensive studies to determine the contributions of de novo, salvage and dietary sources.
Monosaccharide therapy presents an exciting therapeutic opportunity and a compelling argument for addressing fundamental biochemical questions about the origins and contributions of these sugars to glycosylation, how they enter and exit cells, their efficiency of reutilization, their ports of entry and/or the specific transporters required for their uptake. This is an unmapped landscape, and the studies here join the established literature in showing that each cell type will have its own confectionary preferences. Knowing the fundamental biochemistry, employing physiological conditions and carefully measuring the contributions of each will be necessary. So let's get started.
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The author declares no competing financial interests. adding 200 µM sialic acid to the water within 24 h post fertilization. Thus, free sialic acid bypassed the metabolic block. Although it is difficult to extrapolate from the fish model to humans, perhaps supplements might help patients. This is not a novel concept.
A therapeutic confectionary menu Sugar (monosaccharide) supplements benefit patients with other glycosylation disorders.
Patients with MPI-CDG bypass their defect (reducing the conversion of fructose-6-P to mannose-6-P) with a few grams of oral mannose that corrects protein-losing enteropathy, coagulopathy and hypoglycemia 2 . The rare patients with fucose deficiency (SLC35A2-CDG) have frequent infections and highly elevated numbers of neutrophils, but provide them with a few grams of fucose supplements, and their neutrophil levels normalize in a few days 3 . Fucose restores synthesis of depleted fucosylated glycans found on precursor cells in the bone marrow. Galactose supplements normalize glycosylation of liver-derived glycoproteins in patients with PGM1-CDG (a deficiency of the interconversion of glucose-6-P and glucose-1-P) 4 . ManNAc and sialic acid are in clinical trials now for patients with adult-onset inclusion-body myopathy
Another patient with IDD and a similar clinical phenotype, but with an unknown mutation, initially underwent high-resolution metabolic profiling that showed accumulation of ManNAc in plasma, urine and cerebrospinal fluid. The team surmised that the ManNAc probably came from intracellular precursor ManNAc-6-P (Fig. 1) , strongly suggestive of mutations in NANS, which they then confirmed. Similar analysis of the other patients demonstrated that they also accumulated ManNAc in their body fluids and ManNAc-6-P in fibroblasts. Metabolic tracers for sialic acid and ManNAc showed that the patients' cells incorporated the former, but not the latter, highlighting the impact of the mutations on the de novo pathway. Surprisingly, bulk fibroblast glycoproteins and liver-derived plasma glycosylation biomarkers showed normal sialylation. Therefore, sialic acid seems to be salvaged from either degraded glycoproteins or from the diet.
Could sialic acid supplements benefit these patients? To investigate this, the team knocked down nansa (the ortholog of NANS) in zebrafish embryos, which displayed abnormal skeletal development when assessed at 6 days post fertilization. The skeletal abnormality could be partially rescued by simply 
